Mutations of SLC26A4 are a common cause of human hearing loss associated with enlargement of the vestibular aqueduct. SLC26A4 encodes pendrin, an anion exchanger expressed in a variety of epithelial cells in the cochlea, the vestibular labyrinth and the endolymphatic sac. Slc26a4 D/D mice are devoid of pendrin and develop a severe enlargement of the membranous labyrinth, fail to acquire hearing and balance, and thereby provide a model for the human phenotype. Here, we generated a transgenic mouse line that expresses human SLC26A4 controlled by the promoter of ATP6V1B1. Crossing this transgene into the Slc26a4 D/D line restored protein expression of pendrin in the endolymphatic sac without inducing detectable expression in the cochlea or the vestibular sensory organs. The transgene prevented abnormal enlargement of the membranous labyrinth, restored a normal endocochlear potential, normal pH gradients between endolymph and perilymph in the cochlea, normal otoconia formation in the vestibular labyrinth and normal sensory functions of hearing and balance. Our study demonstrates that restoration of pendrin to the endolymphatic sac is sufficient to restore normal inner ear function. This finding in conjunction with our previous report that pendrin expression is required for embryonic development but not for the maintenance of hearing opens the prospect that a spatially and temporally limited therapy will restore normal hearing in human patients carrying a variety of mutations of SLC26A4.
Introduction
Enlargement of the vestibular aqueduct (EVA; OMIM #600791) is a malformation of the temporal bone that is commonly observed in children with sensorineural hearing loss [1, 2, 3, 4, 5] . Mutations of SLC26A4 are the most common cause for EVA-associated hearing loss that can either be non-syndromic (DFNB4; OMIM # 600791) or syndromic with enlargement of the thyroid gland (Pendred syndrome; OMIM #274600). SLC26A4 codes for the anion exchanger pendrin that transports anions such as Cl 2 , I 2 and HCO 3 2 [6, 7] . Although EVA is a malformation of the temporal bone, it is not the cause for hearing loss since no correlation was found between the degree of EVA and the severity of hearing impairment [8] . EVA, however, is an indication of an enlargement of the endolymphatic duct epithelium that was present during embryonic development. Cartilage cells that form in the periphery of the endolymphatic duct epithelium preserve the diameter of the duct in a 'fossil-like' record when they give rise to the bone of the vestibular aqueduct.
The mature inner ear consists of seven interconnected fluid spaces that house six sensory organs ( Fig. 1): The cochlea for hearing, the utricle and saccule for sensing linear acceleration including gravity, and three ampullae with semicircular canals for sensing angular acceleration in three spatial axes. The seventh fluid compartment is the endolymphatic duct and sac, which is devoid of sensory cells and which is suspected to play a role in fluid homeostasis [9, 10] . Pendrin is expressed in a variety of epithelial cells that enclose endolymph, which is the luminal fluid of the inner ear (Fig. 1) . Pendrin is expressed in outer sulcus, spiral prominence and spindle-shaped cells in the cochlea, transitional cells in the utricle, saccule and ampullae and mitochondria-rich cells (synonym: Forkhead-related or FORE cells) of the endolym-phatic sac [11, 12] . Each cell type represents a small domain in the heterogeneous epithelium that encloses endolymph. The many locations and cell types that express pendrin in a normal inner ear made the goal to restore function through restoration of expression look futile unless some sites of expression were more important than others.
The earliest onset of pendrin expression in the murine inner ear occurs in the endolymphatic sac at embryonic day E11.5, which precedes the onset of expression in the cochlea by 3 days, in the saccule and utricle by 4 days, and in the ampullae by 5 days [13] . The expression in the endolymphatic sac surges dramatically at E14.5, a time in development when there is very little pendrin expressed elsewhere in the inner ear [13] .
Studies in a mouse model, Slc26a4 D/D , have revealed that loss of pendrin leads to an enlargement of endolymph volume followed by an acidification and a failure to develop normal hearing and balance [13, 14] . The onset of the enlargement in the cochlea and the endolymphatic sac occurs at E14.5 which precedes the onset of the luminal acidification by 1 day in the cochlea and by 3 days in the endolymphatic sac [13] . The enlargement develops in Slc26a4 D/D mice between E14.5 and E18.5, which is the phase of rapid growth of the cochlea [4] . The coincidence of the surge in pendrin expression in the endolymphatic sac at E14.5 and the onset of the enlargement in Slc26a4 D/D mice points to the importance of pendrin expression in the endolymphatic sac for inner ear fluid homeostasis.
We hypothesized that restoration of pendrin expression in the endolymphatic sac would prevent enlargement and permit normal development of the cochlea and the vestibular labyrinth including the acquisition of sensory function. To test this hypothesis, we generated a mouse line that expresses human pendrin SLC26A4 controlled by the promoter of the B1-subunit of the human vacuolar H + ATPase (ATP6V1B1) and crossed this transgene into Author Summary
Mutations of SLC26A4 are the most common cause for hearing loss associated with a swelling of the inner ear. This human disease is largely recapitulated in a mutant mouse model. Mutant mice lack Slc26a4 expression and their inner ears swell during embryonic development, which leads to failure of the cochlea and the vestibular organs resulting in deafness and loss of balance. SLC26A4 is normally found in the cochlea and vestibular organs of the inner ear as well as in the endolymphatic sac, which is a non-sensory part of the inner ear. The multitude of sites where SLC26A4 is located made the goal to restore function through restoration look futile, unless some sites were more important than others. Here, we generated a new mutant mouse that expresses SLC26A4 in the endolymphatic sac but not in the cochlea or the vestibular organs of the inner ear. Fantastically, this mouse did not develop the detrimental swelling of the inner ear and even more exciting, the mouse developed normal hearing and balance. Our study provides the proof-of-concept that a therapy aimed at repairing the endolymphatic sac during embryonic development is sufficient to restore a life-time of normal hearing and balance.
the Slc26a4 D/D line to generate mice that lack expression of mouse pendrin but express human pendrin in the endolymphatic sac. No expression of pendrin protein was detected in these mice in the cochlea or the vestibular labyrinth but in mitochondria-rich cells of the endolymphatic sac. Analysis of this mouse model revealed normal hearing and balance function. Our data indicate that the expression of pendrin solely in the endolymphatic sac of the inner ear is sufficient to permit the development of normal hearing and balance. 
Results

Generation
mRNA expression
Expression of Atp1a1, Atp6v1b1, Slc26a4 and SLC26A4 was determined by quantitative RT-PCR and normalized to the expression of 18S rRNA (Fig. 2) . The highest levels of Atp6v1b1 and Slc26a4 mRNA among the different inner ear tissues were found in the endolymphatic sac ( Fig. 2B and C D/+ mice remained undetermined, since the efficiency of the reverse transcription of Figure 2 . Atp1a1, Atp6v1b1, Slc26a4, and SLC26A4 mRNA levels in inner ear tissues. Expression was determined by quantitative RT-PCR performed on total RNA. Total RNA was isolated from microdissected tissues obtained from Tg(2);Slc26a4 D/+ (A-D) and Tg(+);Slc26a4 D/D mice (E-H). Endolymphatic sacs (ES) were isolated from mice at age E17.5. Cochleae were isolated at ages E17.5 (C1) and P2 (C2). Vestibular labyrinths (VL), consisted of saccule, utricle, ampullae and semicircular canals without endolymphatic sacs, were isolated at age P8. The expression of endogenous mouse Atp1a1, Atp6v1b1, and Slc26a4, and of transgenic human SLC26A4 mRNA was normalized to the expression of 18S rRNA. Note that the expression pattern of human SLC26A4 in Tg(+);Slc26a4 D/D mice resembles the pattern of mouse Slc26a4 in Tg(2);Slc26a4 D/+ mice (both patterns highlighted in red). Numbers inside graphs represent the number of experiments. doi:10.1371/journal.pgen.1003641.g002 mRNA into cDNA remains generally unknown in quantitative RT-PCR experiments. Taken together, the data demonstrate that the transgene restored pendrin mRNA expression to the endolymphatic sac, the cochlea and the vestibular labyrinth of the inner ear.
Protein expression -eGFP expression
The ability of the ATP6V1B1 promoter to drive protein expression in different tissues including the cochlea, the vestibular labyrinth and the endolymphatic sac was evaluated in a transgenic mouse line, Tg(B1-eGFP) in which the expression of eGFP is controlled by the same 6.9 kb promoter of the human ATP6V1B1 gene that drives the expression of human pendrin in Tg(+);Slc26a4 D/D mice [16] . No expression of eGFP was detected in the cochlea or the vestibular labyrinth of E15.5 Tg(B1-eGFP) mice, although expression was present in the endolymphatic sac and the kidney (Fig. 3) . These data suggest that the ATP6V1B1 promoter does not drive protein expression in the cochlea or the vestibular labyrinth. (Fig. 4B) , which suggests that the antibody recognizes both mouse and human pendrin. The observation that pendrin was detected at (Fig. 5D ). These data demonstrate that the transgene drives pendrin expression in the endolymphatic sac and that the introduction of the transgene rescued the malformation [10, 14] . (Fig. S1C) suggesting that the introduction of the transgene rescued the cochlear malformation previously described in Slc26a4 D/D mice, which includes a ,10-fold enlargement of the cochlea [12, 14] . No detectable pendrin expression was found in the spiral prominence or outer sulcus epithelium of the cochlea in Tg(+);Slc26a4 D/D mice although prominent expression was observed in these cells in positive controls ( Fig. 7 and S1 ). The absence of pendrin in Tg(+); Slc26a4 D/D mice was observed with two different anti-pendrin antibodies (Pds #1 and Pds #2). The patterns of pendrin expression in the positive controls, Tg(2);Slc26a4 D/+ and Tg(+);Slc26a4 D/+ mice, were similar for both antibodies to the pattern previously observed in Slc26a4 D/+ mice [11, 12, 13] . Expression of pendrin was further examined in whole-mounted 
Protein expression -Western blotting
Gross morphology of the cochlea
Endocochlear potential and pH
The endocochlear potential and the difference in pH between endolymph and perilymph was measured with double-barreled ion selective electrodes in Tg (2) (2);Slc26a4 D/D mice failed to develop a normal endocochlear potential and the pH of endolymph was lower ( = more acidic) than in perilymph, as previously reported [18] . In contrast, Tg(+);Slc26a4 D/+ mice, as reported for Slc26a4 D/+ mice [18] , developed a normal endocochlear potential and a normal endolymphatic pH that was higher ( = more alkaline) than in perilymph. Similar to Tg(+);Slc26a4 D/+ mice, Tg(+);Slc26a4 D/D mice developed a normal endocochlear potential and a normal endolymphatic pH even though no detectable pendrin expression was observed in the cochlear epithelium. These data demonstrate that the introduction of the transgene, which rescued the malformation, also rescued the loss of the endocochlear potential and the loss of normal endolymphatic pH homeostasis.
Hearing
Hearing tests were based on auditory brain stem recordings and thresholds in response to tone bursts of 8 kHz, 16 (Fig. 9C ). These findings demonstrate that the introduction of the transgene rescued normal hearing although the cochlea did not express detectable levels of pendrin. We next evaluated whether the rescued hearing phenotype in Tg(+);Slc26a4 D/D would be stable through at least 3 months of age. Auditory brain stem recordings were performed in Tg(+);Slc26a4 D/+ mice ( Fig. 9D-F 
Histology and pendrin expression in the vestibular labyrinth
Sections and whole-mounted specimens of vestibular tissues were prepared for immunocytochemistry from Tg(+);Slc26a4 mice with both antibodies were similar to the pattern previously described in Slc26a4 D/+ mice [11, 12] .
Otoconia
Vestibular labyrinths were isolated by microdissection from Tg(2);Slc26a4 D/D , Tg(+);Slc26a4 D/D and Tg(+);Slc26a4 D/+ mice and the roof of the utricle was removed to permit an unobstructed view onto the utricular macula ( Fig. 11A-C mice were ,10-fold larger than normal otoconia (Fig. 11D) 
Discussion
In this study we generated a mouse that expresses human pendrin in the endolymphatic sac but lacks detectable pendrin protein expression in the cochlea or in the vestibular labyrinth. The most biologically interesting and clinically relevant observation of this study is that this mouse develops normal hearing and balance. Our findings support the hypothesis that pendrin expression in the endolymphatic sac is chiefly responsible for the development of normal endolymph volume, that lack of pendrin in the endolymphatic sac is mainly responsible for the development of the membranous labyrinth enlargement in Slc26a4 D/D mice, and that the complex inner ear pathology found in Slc26a4 D/D mice is largely a consequence of the enlargement during embryonic development. This hypothesis was based on the studies in Slc26a4 D/D mice that revealed that the enlargement is a key event on the path toward organ failure resulting in deafness and vestibular dysfunction [12, 13, 18] and on studies in Foxi1 2/2 mice that lack pendrin expression in the endolymphatic sac, develop an enlargement of the inner ear, but express pendrin in the cochlea and the vestibular labyrinth [19] .
To test our hypothesis, we generated a transgenic mouse, Tg(B1-hPDS), which expresses human SLC26A4 (previously named PDS) controlled by the promoter of ATP1V1B1 [15] . The ability of the promoter of ATP1V1B1 to control gene expression had previously been evaluated in a transgenic mouse that expresses eGFP controlled by the promoter of ATP6V1B1 [16, 20] . Expression of eGFP had been found in this mouse in intercalated cells of the renal collecting duct, and in narrow and clear cells of the epididymal epithelium of adult mice [16] . We found expression of eGFP in the embryonic kidney and in mitochon- dria-rich cells of the endolymphatic sac but not in the cochlea or the vestibular labyrinth (Fig. 3) . Expression in mitochondria-rich cells of the endolymphatic sac was expected since these cells are members of the FORE family (forkhead related) of cells. FORE cells express FOXI1, which drives the expression of Atp6v1b1 and Slc26a4 [21, 22, 23] . Consistently, mitochondria-rich cells of the endolymphatic sac express the mRNAs Atp6v1b1 and Slc26a4 [24, 25] and the corresponding proteins, the B1-subunit of the vH + ATPase and pendrin [11, 23] . The onset of expression of Atp6v1b1 in the endolymphatic sac is at E11.5, which is similar to the onset of pendrin [13, 26] . Thus, it was likely that the transgene Tg(B1-hPDS) would drive a timely expression of pendrin in mitochondria-rich cells of the endolymphatic sac.
Although FOXI1 drives the expression of Atp6v1b1 and Slc26a4 in FORE cells such as the mitochondria-rich cells of the endolymphatic sac, the expression of Atp6v1b1 and Slc26a4 is not limited to FORE cells. Indeed, Slc26a4 is expressed in the inner ear in spiral prominence and outer sulcus epithelial cells as well as in spindle-shaped cells of the cochlea and in transitional cells of the vestibular labyrinth, none of which are FORE cells [11, 12] . Further, Atp6v1b1 expression has been found in the spiral limbus of the cochlea, which does not contain FORE cells [25, 26] . The expression of Atp6v1b1 in the cochlea provided the possibility that the transgene would drive an ectopic expression of pendrin in the spiral limbus. Our studies of eGFP expression (Fig. 3) and of pendrin expression by Western blotting (Fig. 4) and immunocytochemistry of whole-mounted specimens and sections using two different anti-pendrin antibodies (Pds #1 and Pds #2, Fig. 10 and S2) is consistent with the reported lack of Atp6v1b1 expression in the vestibular labyrinth based on detection by in situ hybridization [25, 26] and by quantitative RT-PCR ( Fig. 2B and F) , which is a more sensitive technique. The observation that human SLC26A4 mRNA but no pendrin nor eGFP protein was detected in the cochlea or the vestibular labyrinth suggests the presence of strong translational regulation [27] . Taken together, our data demonstrate that we have generated a mouse that expresses pendrin in the endolymphatic sac but not in the cochlea or the vestibular labyrinth, although we cannot completely rule out that low levels of pendrin protein expression escaped our detection. Such low pendrin expression is unlikely the reason for the restored endolymphatic volume, since pendrin expression in the cochlea and vestibular labyrinth of Foxi 2/2 mice, which lack pendrin expression in the endolymphatic sac, did not prevent endolymphatic enlargement [19] and since mice that express a mutant pendrin protein that supports anion exchange at a reduced rate are deaf, develop mega-otoconia and are balance impaired [28] . Moreover, hypomorphic mutant alleles of SLC26A4 show no difference in the resulting auditory phenotype from that of functional null alleles in patients with Pendred syndrome [29] , indicating that small amounts of pendrin activity are insufficient to rescue hearing in humans.
Measurements of the endocochlear potential and pH revealed that the introduction of the transgene, which rescued normal endolymph volume, also rescued the loss of the normal endocochlear potential and the loss of the normal endolymphatic pH homeostasis (Fig. 8 ). It appears that the Cl 2 /HCO 3 2 exchanger pendrin, which is normally expressed in the apical membranes of spiral prominence and outer sulcus epithelial cells, is not the sole mechanism responsible for the alkaline pH of endolymph in a normally developed cochlea. A similar conclusion can be drawn based on measurements in the doxycycline-inducible Slc26a4 mouse model where termination of pendrin expression at P6 led to the development of a nearly normal endocochlear potential and of a nearly normal alkaline pH [30] . We hypothesize that the epithelial barrier enclosing endolymph is permeable to H + , OH 2 and HCO 3 2 and that the pH of endolymph follows the endocochlear potential. Hearing and balance tests in Tg(+);Slc26a4 D/D mice revealed normal sensory function ( Fig. 9 and 12 D/ D mice that were recently generated in a mixed background of C57BL/6 and CBA. DNA from the three background strains, 129S6, C57BL/6 and CBA, which differ in their hearing thresholds, are expected to comprise variable amounts of the genomes of individual mice. Hearing thresholds for 1 to 3 monthold 129S6, C57BL/6 and CBA mice range between 20-35 dB-SPL at 8 kHz, 10-28 dB-SPL at 16 kHz and 20-50 dB-SPL at 32 Hz [18, 31, 32, 33, 34, 35] . In general, 129S6, C57BL/6 and CBA mice have similar thresholds at 8 kHz, whereas at 16 and 32 kHz CBA mice have lower thresholds than 129S6 and C57BL/ 6 mice. Thus, the greater variability in hearing thresholds that was observed at 32 kHz particularly in Tg(+);Slc26a4 D/D may be due to a variability in the mixture of these background strains.
Our observation that normal hearing developed in the absence of pendrin expression in the cochlea in combination with the published finding that normal hearing was maintained when pendrin expression was terminated after completed development [30] , could suggest that pendrin in the cochlea has no physiologic significance beyond the developmental phase. However, it is also conceivable that pendrin-mediated HCO 3 2 secretion provides a buffer that stabilizes the pH in the lateral wall tissues as well as in endolymph, and that this buffering is important during stress situations associated with normal life. Pendrin expression may indeed be important for the maintenance of hearing into advanced age.
In summary, we demonstrated that restoration of pendrin to the endolymphatic sac is sufficient to restore normal inner ear function. This implies that pendrin in the endolymphatic sac is more important for the development of normal hearing than pendrin expression in the cochlea and more important for the development of normal balance than pendrin expression in the vestibular labyrinth. This finding, in conjunction with our previous report that pendrin expression is required for embryonic development but not for the maintenance of hearing, opens the prospect that a spatially and temporally limited therapy will restore normal hearing in human patients carrying a variety of mutations of SLC26A4.
Methods
Ethics statement
All animal experiments and procedures at Kansas State University were performed according to protocols approved by the Animal Care and Use Committees at Kansas State University (IACUC#: 2961). All animal procedures at Sorbonne University Paris Cité were performed according to protocols approved by the ethics committee from University Pierre et Marie Curie, and were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 93-23, revised 1985).
Generation of Tg(B1-hPDS)
Tg/+ ;Slc26a4 +/+ transgenic mice Human SLC26A4 cDNA was ligated into a pBluescript vector that contained 6.9 kbp of the human ATP6V1B1 promoter [16, 20] . An SV40 late region polyadenylation signal was cloned downstream of the SLC26A4 cDNA. The transgene Tg(B1-hPDS) included the 59-flanking region of the ATP6V1B1 gene extending to but excluding the endogenous translational start codon, the human SLC26A4 cDNA, with its own translational start site, and the SV40 late region polyadenylation signal. The integrity of the transgene was confirmed by restriction digest and bidirectional sequencing of ligation sites. In preparation for injection, the transgene was linearized by SalI and NotI digestion, followed by gel purification using an electroelution method and then concentrated using ElutipD columns (Whatman). The transgene was then further concentrated by ethanol precipitation and resuspended in low EDTA injection buffer (10 mM Tris with 0.1 mM EDTA). Tg(B1-hPDS) transgenic mice were created by the University of Utah transgenic mouse core facility using standard procedures [16, 20] . Genotyping revealed that 63 pups were positive for transgene integration. One founder, which transmitted the transgene in a Mendelian fashion, was crossed with wild-type C57BL/66 CBA F1 mice to establish a colony. Three Tg (B1-hPDS) 
Genotyping
Mice were genotyped for Slc26a4 + and Slc26a4 D alleles by PCR using established primers [14] and for the transgene Tg(B1-hPDS) (Transnetyx, Cordova, TN). Primers for the transgene were designed to amplify a 345 bp PCR-product spanning the hPDS cDNA and the SV40 polyadenylation signal sequence (left primer: 59-aga ggg tca agg ttc cat ttt ag-39; right primer: 59-caa acc aca act aga atg cag tg-39) [15] .
Isolation of embryonic tissues
Time-pregnant dams were deeply anesthetized with 4% tribromo-ethanol (0.014 ml/g body weight, i.p.) and embryos were harvested by laparotomy. Dams and embryos were sacrificed by decapitation. Gestational age was counted from the day when the vaginal plug was detected. This day was set to embryonic (E) day 0.5. Gestational age, however, was verified by evaluating gross morphological features including limbs, digits and the appearance of the pinna and auditory meatus [36, 37] .
Isolation of tissues from postnatal mice
The age of mice was counted from the day of birth, which was set to postnatal (P) day 0. Postnatal mice were deeply anesthetized with 4% tri-bromo-ethanol (0.014 ml/g body weight, i.p.) and sacrificed by decapitation or cardiac perfusion with fixative.
Quantitative RT-PCR
Quantitative RT-PCR was performed on total RNA [17] . Total RNA was isolated from tissues obtained by microdissection from Tg(2);Slc26a4 D/+ and Tg(+);Slc26a4 D/D mice and subjected to quantitative RT-PCR using gene-specific primers for 18S rRNA as well as for mRNA coding for the a-subunit of the mouse Na + / K + ATPase Atp1a1, the B1-subunit of the mouse vH + ATPase Atp6v1b1, mouse pendrin Slc26a4 and human pendrin SLC26A4, which was introduced via the transgene. Postnatal mice were genotyped by PCR prior to tissue collection. Embryonic Tg(2);Slc26a4 D/+ mice were generated by mating Tg (2) Tissues were obtained by microdissection. Endolymphatic sacs (8-10 endolymphatic sacs from 4-5 animals per sample) were obtained from mice at age E17.5. Cochlear ducts (4 cochlear ducts from 2 animals per sample and 2 cochlear ducts from 1 animal per sample) were obtained from mice at ages E17.5 and P2, respectively. Vestibular labyrinths (6 vestibular labyrinths from 3 animals per sample) were obtained from mice at age P8. Total RNA was isolated from microdissected tissues (RNeasy micro kit, Qiagen, Valencia, CA, USA), treated with DNAse (RNeasy micro kit), combined with RNA storage solution (Applied Biosystems/ Ambion, Austin, TX), adjusted to a concentration of 10 ng/ml, and stored at 280uC.
Quantity and quality of total RNA were evaluated by microfluidic electrophoresis (BioAnalyzer, Agilent, Santa Clara, CA), by microliter absorption photometry (Nanodrop, Wilmington, DE) and by quantitative RT-PCR of 18S rRNA. RNA samples were accepted for quantitative RT-PCR only when they were free of contamination and excellent RNA quality. RNA quality was quantified by the RNA integrity number (RIN) on a scale from 0 (worst) to 10 (best) (BioAnalyzer, Agilent). RIN numbers for total RNA isolated from E17.5 endolymphatic sac and cochlea were 8.260.3 (n = 3) and 9.260.1 (n = 10).
Chemicals were assembled with the assistance of an automatic pipetting station (Biomek NX p , Beckman Coulter, Fullerton, CA) with hardware modifications and software programming by P.W. Quantitative RT-PCR reactions were carried out in 96-well plates with each well containing ,10 ng of total RNA, gene specific primers, and an enzyme mix containing reverse transcriptase and DNA polymerase (iScript, BioRad, Hercules, CA) in a total volume of 25 ml. Reverse transcription was performed for 10 min at 50uC and terminated by heating to 95uC for 5 min (OneStepPlus, Applied Biosystems, Foster City, CA). PCR consisted of 40 cycles of 10 s melting at 95uC, 30 s annealing and elongation at 58uC, and 15 s hot-measurement at 78uC (OneStepPlus, Applied Biosystems).
Left and right primers (exon, product size) were for 18S 59-gag gtt cga aga cga tca ga-39 and 59-tcg ctc cac caa cta aga ac-39 (316 bp), for Atp1a1 59-tgc ccg cct caa cat tcc-39 (exon 14) and 59-gac aca tca gag cca aca atc c-39 (exon 16, 291 bp), for Atp6v1b1 59-tga ccc gaa act aca tca cc-39 (exon 1) and 59-gcc aga gcc att gaa aat cc-39 (exon 5, 305 bp), for mouse Slc26a4 59-tct gat gga ggc aga gat ga-39 (exon 20) and 59-ggc cag cct aac aga gac ag-39 (exon 21, 430 bp), and for human SLC26A4 were 59-tcc caa agt gcc aat cca ta-39 and 59-aca tca agt tct tct tcc gtc ag-39 (360 bp). Primer pairs for Atp1a1, Atp6v1b1, mouse Slc26a4 spanned introns to prevent amplification of genomic DNA. Primer pairs for mouse Slc26a4 detected the Slc26a4 + allele as well as the Slc26a4 D allele that is lacking exon 8 [14] . Left and right primers for mouse Slc26a4 differed by 7 and 10 nucleotides from the corresponding human sequence and left and right primers for human SLC26A4 differed in 4 and 6 nucleotides from the corresponding mouse sequence, thereby maximizing species-specific amplification. Since the human transgene did not contain introns, some reactions were carried out without reverse transcriptase to determine whether products of SLC26A4 originated from cDNA rather than from genomic DNA. These experiments revealed no evidence for significant amplification of genomic DNA. Amplification of a single product of the appropriate size was verified by microfluidic electrophoresis (BioAnalyzer, Agilent). ) that was obtained from calibration experiments, Product Size is the size of the product in base pairs (bp), Weight bp is average weight of one bp (660 g/mol), Efficiency is the PCRefficiency obtained from the slope of the log-linear phase of the growth curve [38] and C t is the cycle at which the fluorescence of the product molecules reaches a common threshold chosen in the middle of the log-linear part of the growth curve.
Paint-fill
Bisected heads of embryos age E15.5 were fixed overnight in Bodian's fixative, contained (vol/vol) 75% ethanol, 5% acetic acid, and 5% formalin in water. Heads were then dehydrated overnight in 100% ethanol and cleared in methyl-salicylate [39, 40] . The membranous labyrinth was injected via the lateral wall of the basal turn of the cochlea and via the endolymphatic sac with diluted paint (Liquid Paper, Newell Rubbermaid, Atlanta, GA, 0.1-0.2% in methyl-salicylate) using a fine glass-electrode, a manipulator (NM-151 Narishige) and a micrometer-driven oil-filled microinjector (CellTram Vario, Eppendorf, Hamburg, Germany). For each genotype, at least three inner ears were injected.
Direct fluorescence of eGFP
Whole mounts of fresh cochlear ducts, endolymphatic sacs and slices of kidney were prepared from E15.5 Tg(B1-eGFP) mice and visualized with a fluorescence microscope (AxioScope, Carl Zeiss Göttingen).
Western blotting
Crude membrane preparations of the inner ear. Soft tissues from 8 cochleae and 8 vestibular labyrinths devoid of endolymphatic sacs from adult mice were collected by microdissection in Cl 2 -free solution and pooled and homogenized in 500 ml Tris-sucrose buffer. Cl 2 -free solution contained (mM) 150 Na-gluconate, 1.6 K 2 HPO 4 , 0.4 KH 2 PO 4 , 4 Ca-gluconate 2 , 1 MgSO 4 and 5 glucose, pH 7.4. Tris-sucrose buffer contained (mM) 250 sucrose, 50 Tris-HCl, 5 EDTA, pH = 7.4, and proteinase inhibitor cocktail (Cat# PI-87786 Fisher, Pittsburgh, PA). Homogenization involved a pestle/1.5 ml Eppendorf vial and a Potter-Elvehjem tissue grinder (3 strokes at 1,250 rpm; Cat# K885512-0020, Fisher). Nuclei and debris were sedimented by centrifugation (6 min, 600 g, 4uC, Micromax RF, International equipment, Needham Heights, MA) and the supernatant contain-ing membranes was collected. Pellets were washed 36 with 100 ml Tris-sucrose buffer. Supernatants were pooled and membranes were pelleted by centrifugation (1 hr, 21,000 g, 4uC, Micromax RF). Membranes were suspended in 30 ml Tris-sucrose buffer and protein content was quantified (BCA assay, Cat# 23227, Fisher; Absorption photometer, Nanodrop).
Crude membrane preparations of kidneys. Kidneys (,1 g wet weight) were sliced, frozen in liquid N 2 , pulverized, transferred into 8 ml Tris-sucrose buffer and homogenized. Homogenization involved pestles fitting 1.5 ml Eppendorf vials and the Potter-Elvehjem tissue grinder (3 strokes at 1,250 rpm). Nuclei and debris were sedimented by centrifugation (6 min, 600 g, 4uC, Micromax RF) and the supernatant containing membranes was collected. Pellets were washed 36 with 2 ml Tris-sucrose buffer. Supernatants were pooled and membranes were pelleted by centrifugation (1 hr, 21,000 g, 4uC, Micromax RF). Membranes were suspended in 200 ml Tris-sucrose buffer and protein content was quantified (BCA assay).
Gel-electrophoresis, blotting and protein detection. Crude membranes were solubilized, denatured and reduced for 1 hr at 37uC in LDS sample buffer (Cat#: NP0007; Invitrogen) supplemented with 50 mM DTT. Proteins were resolved by gel-electrophoresis (4-12% Bis-Tris gels (Cat#: NP0326, Invitrogen) using a MOPS-SDS running buffer supplemented with an antioxidant (Cat#: NP0005, Invitrogen) and transferred onto PVDF membranes (BioRad, 3 hrs at 30 V). PVDF membranes were blocked for 1 hr at RT in TBST solution containing 3% BSA. TBST solution contained 20 mM Tris-base, 68 mM NaCl, and 1% Tween-20. Blocked PVDF membranes were incubated overnight at 4uC with primary antibody in TBST solution with 3% BSA. Primary antibodies were a rabbit antipendrin antibody (Pds #2; 1:200) and a polyclonal rabbit antimouse b-actin antibody (1: 1,000; Cat#: A2066, Sigma-Aldrich). Pds #2 was raised against the last 15 amino acids of the Cterminal of mouse pendrin [30] . Human pendrin differs in only 1 of these 15 amino acids. PVDF membranes were washed 563 min in TBST solution and then incubated for 1 hr at RT with the secondary antibody, goat anti-rabbit poly-HRP (Cat#: PI32260, Fisher) diluted in TBST solution with 3% BSA. The dilution of the secondary antibody was 1:2,500 for labeling the Pds #2 antibody and 1:10,000 for labeling the b-actin antibody. The membranes were washed 365 min in TBST solution. HRP was detected by chemiluminescence (SuperSignal Femto, Cat# PI34095, Fisher). The signal was integrated over 2-5 min by cooled CCD camera (ImageStation 4000R, Kodak).
Immunocytochemistry
Fixation. Isolated tissues from embryonic mice were fixed by submersion in PBS-formaldehyde solution at 4uC. PBS-formaldehyde solution consisted of 4% formaldehyde (Electron Microscopy Sciences, Hatfield PA) in a solution that contained (in mM) 137 NaCl, 2.7 KCl, 10.1 Na 2 HPO 4 , 1.8 KH 2 PO 4 . Tissues from postnatal animals were fixed by cardiac perfusion followed by perilymphatic perfusion. Cardiac perfusion was initiated with Cl 2 -free solution (6 ml, 1 min) and followed by Cl 2 -free solution with 4% formaldehyde (12 ml, 2 min). Perilymphatic perfusion consisted of an infusion of Cl 2 -free solution with 4% formaldehyde (25 ml, 5 min) through the round and oval window of the cochlea.
Cryosections. Fixed temporal bones were decalcified 18-24 h in 10% EDTA, processed through a sucrose gradient and infiltrated with polyethylene glycol. Mid-modiolar cryosections (12 mm, CM3050S, Leica, Nussloch, Germany) were blocked in PBS-TX (137 mM NaCl, 10.1 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 2.7 mM KCl, pH 7.4 with 0.15% Triton X 100) and 5% bovine serum albumin. Slides were incubated overnight at 4uC with primary antibody in PBS-TX with 2.5% BSA. Primary antibodies were two rabbit anti-pendrin antibodies (Pds #1; 1:200; a kind gift from Dr. Søren Nielsen, University of Aarhus, Denmark and Pds #2, 1:1,000) and a polyclonal FITC-conjugated goat anti-eGFP antibody (Cat#: GTX26662, GeneTex, San Antonio, TX). Pds #1 was raised against the last 22 amino acids of the C-terminal of mouse pendrin. Human pendrin differs in 6 of these 22 amino acids [13, 41] . Slides were washed with PBS-TX and, where appropriate, incubated for 1 h at RT with secondary antibody (1:1,000, goat anti-rabbit Alexa 594, Invitrogen, Carlsbad, CA). After washing with PBS-TX, sections, where appropriate, were stained with phalloidin 488 (1:40; Invitrogen) to mark F-actin and DAPI (1:1,000; Invitrogen) to mark nuclei, washed again and cover-slipped with mounting medium (Vectashield HardSet Mounting Medium, Vector laboratories, Burlingame, CA).
Whole-mounted specimens. Tissues were obtained by microdissection from fixed temporal bones, washed in PBS-TX, and blocked with 5% bovine serum albumin in PBS-TX. Tissues were incubated overnight at 4uC with primary antibodies in PBS-TX with 2.5% BSA. Primary antibodies were a rabbit antipendrin antibody (Pds #1; 1:200) or a polyclonal FITCconjugated goat anti-eGFP antibody (GeneTex). Slides were washed with PBS-TX and, where appropriate, incubated for 1 h at RT with secondary antibody (1:1,000, goat anti-rabbit Alexa 594, Invitrogen). After washing with PBS-TX, tissues were stained with phalloidin 488 or phalloidin 594 (1:40; Invitrogen) and DAPI (1:1000; Invitrogen), washed again and cover-slipped with mounting medium (VectaShield HardSet Mounting Medium, Vector laboratories, Burlingame, CA).
Confocal microscopy. Immunocytochemistry of cryosections and whole-mounted specimens were viewed by confocal microscopy (LSM 510 Meta, Carl Zeiss, Göttingen, Germany). Laser scanning bright-field images were collected to aid orientation.
Endocochlear potential and pH difference between endolymph and perilymph
Mice were anesthetized with 4% tri-bromo-ethanol for in situ measurements of the endocochlear potential and pH with doublebarreled microelectrodes. Measurements were made in the basal turn of the cochlea by a round-window approach through the basilar membrane of the first turn of the cochlea [18, 42] . The surgical cavity was covered with liquid Sylgard 184 (Dow Corning) to limit the loss of tissue CO 2 into ambient air. Double-barreled glass microelectrodes were pulled (micropipette puller PD-5; Narishige) from filament-containing glass tubing (1B100F-4; World Precision Instruments) and baked at 180uC for 2 h to ensure dryness. One barrel was silanized by a 30 s exposure to 0.008 ml dimethyldichlorosilane (40136; Fluka). After silanization, microelectrodes were baked again at 180uC for 3 h and tips were broken to a final O.D. of ,3 mm. The reference barrel was filled with 150 mM KCl and the ion-selective barrel was filled at the tip with liquid ion exchanger (Hydrogen ionophore IICocktail A, 95297; Fluka) and back-filled with buffer solution (500 mM KCl, 20 mM HEPES, pH 7.4).
Each barrel of the double-barreled microelectrode was connected via a Ag/AgCl 2 electrode to an electrometer (FD223, World Precision Instruments). A flowing KCl electrode (1 M KCl in 0.2% agar) was inserted under the skin of the animal to serve as ground electrode. Data were recorded in analog (BD12E Flatbed recorder, Kipp & Zonen, Delft, The Netherlands) and digital form (DIGIDATA 1322A and AxoScope 10, Axon Instruments, Union City, CA). pH electrodes were calibrated in situ at 37uC using three calibration solutions with different pH values. Calibration solutions contained (in mM): pH 6: 130 NaCl, 20 MES; pH 7: 130 NaCl, 20 HEPES; and pH 8: 130 NaCl, 20 HEPES. pHsensitive electrodes had a slope of 56.9 6 0.3 mV/pH unit (n = 11).
Hearing tests
Mice were deeply anesthetized with a mixture of dexmedetomidine and ketamine (0.375 mg/Kg body weight dexmedetomidine and 56 mg/kg body weight ketamine; i.p.) and placed on a thermal pad to maintain normal body temperature. The mastoid, vertex and ventral neck region of the animal were connected via sub-dermal platinum needle electrodes (F-E2, Astro Med, Rhode Island, RI) and short (31 cm) leads to the main channel, reference channel and ground of the preamplifier, respectively. Auditory brainstem recordings were performed in a custom constructed, electrically shielded and sound-attenuated chamber (inner dimensions: 23 cm623 cm623 cm) using a digital data acquisition system (BioSig32 software, RA4LI Preamplifier, RP2.1 Enhanced Real Time Processor, PA5 Programmable Attenuator, ED1 Electrostatic Speaker Driver, Tucker-Davis Technologies, Alachua, FL). Tone burst stimuli were presented (21 per sec) via a free field electrostatic speaker (SigGen software, ES1 speaker, Tucker Davis). Acoustic stimuli were calibrated using a 1/4 inch condenser microphone (SigCal IRP4.2 software, Tucker Davis, PS9200 microphone, Acoustical Interface, Belmont, CA) placed at the location of the mouse head. Tone bursts (2 ms duration, 0.5 ms gate time; 8, 16 and 32 kHz) were presented with alternating phase (0 and 180u). Responses, recorded over 10 ms, were filtered (300 Hz high pass, 3000 Hz low pass and 60 Hz notch) and 1000 recordings were averaged. Tone burst stimuli were presented at intensities varying between 90 and 0 dB SPL in 5 dB intervals. Auditory thresholds were obtained by a visual comparison of wave forms. After the procedure, mice were rapidly recovered from anesthesia with atipamizole (1.875 mg/kg body weight; i.p.).
Balance tests
Balance testing consisted of determining the time that mice could balance on a rotating 10 rod with rotations ramping up from 4 to 40 rpm in 60 s (RotaRod, IITC Life Science, Woodland Hills, CA). Test chambers were cushioned with bubble-foil to provide a soft landing for mice falling off the rod. 
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